PMID- 34600572
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 2056-9920 (Print)
IS  - 2056-9920 (Electronic)
IS  - 2056-9920 (Linking)
VI  - 7
IP  - 1
DP  - 2021 Oct 2
TI  - A 24 month follow-up of refractory macular holes treated with an autologous 
      transplantation of internal limiting membrane versus retina expansion technique.
PG  - 57
LID - 10.1186/s40942-021-00329-1 [doi]
LID - 57
AB  - BACKGROUND: To compare the functional and anatomic outcomes at 24 months of eyes 
      with a primary macular hole that failed to close after a prior surgery and were 
      treated with either an autologous transplantation of internal limiting membrane 
      (AT-ILM) or the retina expansion (RE) technique. METHODS: Retrospective, single 
      center, comparative study of 28 eyes with a macular hole that failed to close 
      after a prior vitrectomy. All eyes had a size of >/= 500 mum. Participants were 
      divided into two groups according to the type of intervention performed: AT-ILM 
      group (n = 14) and RE group (n = 14). Main outcomes measured were the MH closure 
      rate assessed by spectral-domain optical coherence tomography (SD-OCT) and the 
      best-corrected visual acuity (BCVA) at 24 months after surgery. RESULTS: Patients 
      in the AT-ILM group experienced a statistically significantly improved 
      post-operative BCVA (median 49.50 letters, range 20-66 letters) over the 
      pre-operative BCVA (median 39 letters, range 18-52 letters) (p-value = 0.006 
      Wilcoxon paired sample test). In contrast, patients in the RE group did not 
      achieve a statistically significant improvement (p-value = 0.328, Wilcoxon paired 
      sample test). The median pre-operative BCVA was 35 letters (range 18-52 letters), 
      whereas the median post-operative BCVA was 39 letters (range 16-66 letters). At 
      24 months of follow-up, 85.7% of patients in the AT-ILM group achieved closure 
      compared to 57.1% in the RE group (p-value = 0.209, Fisher's exact test). 
      Multivariate analysis showed that MH size and baseline BCVA were important 
      determinants of post-operative BCVA. The baseline MH size was the only 
      significant pre-operative factor that influenced MH closure. CONCLUSIONS: This 
      study demonstrates similar closure rates for both groups however better visual 
      outcomes were obtained with the AT-ILM.
CI  - (c) 2021. The Author(s).
FAU - Alezzandrini, Arturo
AU  - Alezzandrini A
AD  - Oftalmos Centro Oftalmologico de Alta Complejidad, University of Buenos Aires, 
      Buenos Aires, Argentina.
FAU - Dorrego, Camila I
AU  - Dorrego CI
AD  - Sanatorio Otamendi y Miroli, University of Buenos Aires, Buenos Aires, Argentina.
FAU - Cibran, Maria Victoria
AU  - Cibran MV
AD  - Sanatorio Otamendi y Miroli, University of Buenos Aires, Buenos Aires, Argentina.
FAU - Cortina-Revelli, Valentina
AU  - Cortina-Revelli V
AD  - Sanatorio Otamendi y Miroli, University of Buenos Aires, Buenos Aires, Argentina.
FAU - Rocco, Franco D
AU  - Rocco FD
AD  - Sanatorio Otamendi y Miroli, University of Buenos Aires, Buenos Aires, Argentina.
FAU - Zas, Marcelo
AU  - Zas M
AD  - Hospital de Clinicas Jose de San Martin, University of Buenos Aires, Buenos 
      Aires, Argentina.
FAU - Wu, Lihteh
AU  - Wu L
AUID- ORCID: 0000-0002-3387-7058
AD  - Asociados de Macula, Vitreo y Retina de Costa Rica, San Jose, Costa Rica. 
      lihteh@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20211002
PL  - England
TA  - Int J Retina Vitreous
JT  - International journal of retina and vitreous
JID - 101677897
PMC - PMC8487545
OTO - NOTNLM
OT  - Hydrodissection
OT  - ILM free flap
OT  - Macular holes
OT  - Retina expansion
COIS- CID, MVC, VCR and FDR declare that they have competing interests. AA has 
      participated in advisory boards for Roche, Alcon, Bayer and Novartis. MZ has 
      received speaker fees from Alcon, Bayer, Abbvie, Poen and Novo Nordisk. LW has 
      received speaker fees from Bayer and Quantel Medical
EDAT- 2021/10/04 06:00
MHDA- 2021/10/04 06:01
PMCR- 2021/10/02
CRDT- 2021/10/03 20:26
PHST- 2021/04/19 00:00 [received]
PHST- 2021/09/16 00:00 [accepted]
PHST- 2021/10/03 20:26 [entrez]
PHST- 2021/10/04 06:00 [pubmed]
PHST- 2021/10/04 06:01 [medline]
PHST- 2021/10/02 00:00 [pmc-release]
AID - 10.1186/s40942-021-00329-1 [pii]
AID - 329 [pii]
AID - 10.1186/s40942-021-00329-1 [doi]
PST - epublish
SO  - Int J Retina Vitreous. 2021 Oct 2;7(1):57. doi: 10.1186/s40942-021-00329-1.